Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities

Emerging Microbes and Infections

Volumn 8, Issue 1, 2019, Pages 1763-1776

  Matos, Aline da Rocha ^a,b   Wunderlich, Katharina ^a   Schloer, Sebastian ^a   Schughart, Klaus ^c   Geffers, Robert ^c   Seders, Martine ^a   Witt, Marlous de ^a   Christersson, Anmari ^a   Wiewrodt, Rainer ^d   Wiebe, Karsten ^d   Barth, Peter ^e   Hocke, Andreas ^f   Hippenstiel, Stefan ^f   Hönzke, Katja ^f   Dittmer, Ulf ^g   Sutter, Kathrin ^g   Rescher, Ursula ^a   Rodionycheva, Svetlana ^d   Matera, Nicoletta ^d   Ludwig, Stephan ^a   Brunotte, Linda ^a   more..

^a UNIVERSITY OF MÜNSTER   (Germany)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f BERLIN INSTITUTE OF HEALTH   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

antiviral; Human lung explant; IFN subtype; influenza; ISG induction; MxA

Indexed keywords

ALPHA2 INTERFERON; ANTIVIRUS AGENT; EIF2AK2 PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GBP1 PROTEIN; GBP3 PROTEIN; IFITM3 PROTEIN; INTERFERON ALPHA SUBTYPE 4; INTERFERON ALPHA SUBTYPE 16; INTERFERON ALPHA SUBTYPE 5; INTERLEUKIN 6; ISG15 PROTEIN; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MX1 PROTEIN; MYXOVIRUS RESISTANCE PROTEIN A; OASL PROTEIN; PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS RNA; ALPHA INTERFERON; CYTOKINE;

A-549 CELL LINE; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNE RESPONSE; INFLUENZA A VIRUS (H3N2); INNATE IMMUNITY; LUNG PARENCHYMA; MRNA EXPRESSION LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SEASONAL INFLUENZA; UPREGULATION; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN; CLASSIFICATION; DRUG EFFECT; IMMUNOLOGY; INFLUENZA; LUNG; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; VIROLOGY;

A549 CELLS; ANTIVIRAL AGENTS; CYTOKINES; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; LUNG; ORGAN CULTURE TECHNIQUES; VIRUS REPLICATION;

EID: 85076464518     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1080/22221751.2019.1698271     Document Type: Article

References (47)

1. World Health Organization. Vaccines against influenza WHo position paper–November 2012. Wkly Epidemiol Rec. 2012;87:461–476.
2. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–1300. doi: 10.1016/S0140-6736(17)33293-2
3. World Health Organization. Review of global influenza activity, October 2016– October 2017. Wkly Epidemiol Rec. 2017;92:761–780.
4. Soema PC, Kompier R, Amorij JP, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263. doi: 10.1016/j.ejpb.2015.05.023
5. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Wkly Epidemiol Rec. 2018;93:133–152.
6. Hussain A, Ali S, Ahmed M, et al. The anti-vaccination movement: a regression in modern medicine. Cureus. 2018;10:e2919.
7. Frieden TR, Harold Jaffe DW, Director for Science James Stephens AW, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the advisory committee on immunization practices (ACIP), centers for disease control and prevention. MMWR 2011; 6060., [cited 2019 Feb 25]. Available from: http://www.cdc.gov/flu.
8. Ison MG., Antiviral treatments. Clin Chest Med. 2017;38:139–153. doi: 10.1016/j.ccm.2016.11.008
9. Leneva IA, Burtseva EI, Yatsyshina SB, et al. Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010–2011 influenza season in Russia. Int J Infect Dis. 2016;43:77–84. doi: 10.1016/j.ijid.2016.01.001
10. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–923. doi: 10.1056/NEJMoa1716197
11. Takashita E, Ejima M, Ogawa R, et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 2016;132:170–177. doi: 10.1016/j.antiviral.2016.06.007
12. Ludwig S., Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother. 2009;64:1–4. doi: 10.1093/jac/dkp161
13. Hoofnagle JH, Seeff LB., Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451. doi: 10.1056/NEJMct061675
14. Díaz MO, Pomykala HM, Bohlander SK, et al. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 1994;22:540–552. doi: 10.1006/geno.1994.1427
15. Heil F, Hemmi H, Hochrein H, et al. Species-Specific recognition of single-Stranded RNA via Toll-like receptor 7 and 8. Proc Natl Acad Sci USA. 2013;303:1526–1529.
16. Kawai T, Akira S., The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–384. doi: 10.1038/ni.1863
17. Kim N, Now H, Nguyen NTH, et al. Multilayered regulations of RIG-I in the anti-viral signaling pathway. J Microbiol. 2016;54:583–587. doi: 10.1007/s12275-016-6322-2
18. Darnell JE, Kerr LM, Stark GR., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins downloaded from. 1994. [cited 2019 Mar 14]. Available from: http://science.sciencemag.org/.
19. Song J, Li S, Zhou Y, et al. Different antiviral effects of IFNα subtypes in a mouse model of HBV infection. Sci Rep. 2017;7:334. doi: 10.1038/s41598-017-00469-1
20. Matzinger SR, Carroll TD, Fritts L, et al. Exogenous ifn-alpha administration reduces influenza a virus replication in the lower respiratory tract of rhesus macaques. PLoS One. 2011;6:e29255, doi:10.1371/journal.pone.0029255.
21. Matzinger SR, Ma Z-M, Miller CJ, et al. Myxovirus resistance gene a (MxA) expression suppresses influenza a virus replication in alpha interferon-treated primate cells. J Virol. 2013;87:1150–1158. doi: 10.1128/JVI.02271-12
22. Arimori Y, Nakamura R, Yamada H, et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res. 2013;99:230–237. doi: 10.1016/j.antiviral.2013.05.007
23. Kugel D, Kochs G, Obojes K, et al. Intranasal administration of alpha interferon reduces seasonal influenza a virus morbidity in ferrets. J Virol. 2009;83:3843–3851. doi: 10.1128/JVI.02453-08
24. Hayden FG, Gwaltney JM., Intranasal interferon- 2, treatment of experimental Rhinoviral Colds. J Infect Dis. 1984;150:174–180. doi: 10.1093/infdis/150.2.174
25. Treanor JJ, Betts RF, Erb SM, et al. Intranasally administered interferon as prophylaxis against experimentally induced influenza a virus infection in humans. J Infect Dis. 1987;156:379–383. doi: 10.1093/infdis/156.2.379
26. Sarno TC, Greenberg SB, Couch RB, et al. Efficacy and tolerance of intranasally applied recombinant leukocyte a interferon in normal volunteers. J Infect Dis. 1983;148:535–542. doi: 10.1093/infdis/148.3.535
27. Gao LL, Yu S, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28:4445–4451. doi: 10.1016/j.vaccine.2010.03.062
28. Bennett AL, Smith DW, Cummins MJ, et al. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respi Viruses. 2013;7:854–862. doi: 10.1111/irv.12094
29. James CM, Abdad MY, Mansfield JP, et al. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine. 2007;25:1856–1867. doi: 10.1016/j.vaccine.2006.10.038
30. Scagnolari C, Trombetti S, Soldà A, et al. Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. J Interf Cytokine Res. 2011;31:475–479. doi: 10.1089/jir.2010.0125
31. Moll HP, Maier T, Zommer A, et al. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokine. 2011;53:52–59. doi: 10.1016/j.cyto.2010.09.006
32. Dobin A, Gingeras TR., Mapping RNA-seq reads with STAR. Curr Protoc Bioinforma. 2015;51:11.14.1–19. doi: 10.1002/0471250953.bi1114s51
33. Liao Y, Smyth GK, Shi W., The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47. doi: 10.1093/nar/gkz114
34. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2013. Available from: http://www.r-project.org/.
35. Love MI, Huber W, Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8
36. Smyth GK., Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:1–25. doi: 10.2202/1544-6115.1027
37. Benjamini Y, Hochberg Y., Controlling the false discovery rate: a practical and powerful apporach to multiple testing. J R Stat Soc. 1995;57:289–300.
38. Harper MS, Guo K, Gibbert K, et al. Interferon-α subtypes in an ex vivo model of acute HIV-1 infection: expression, potency and effector mechanisms. PLoS Pathog. 2015;11:e1005254. doi: 10.1371/journal.ppat.1005254
39. Zimmermann A, Trilling M, Wagner M, et al. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-γ signaling and antiviral responses. J Exp Med. 2005;201:1543–1553. doi: 10.1084/jem.20041401
40. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87. doi: 10.1126/science.1247005
41. Weinheimer VK, Becher A, Tönnies M, et al. Influenza a viruses target type II pneumocytes in the human lung. J Infect Dis. 2012;206:1685–1694. doi: 10.1093/infdis/jis455
42. Sato S, Li K, Kameyama T, et al. The RNA Sensor RIG-I Dually functions as an innate Sensor and direct antiviral factor for hepatitis B virus. Immunity. 2015;42:123–132. doi: 10.1016/j.immuni.2014.12.016
43. Weber M, Sediri H, Felgenhauer U, et al. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe. 2015;17:309–319. doi: 10.1016/j.chom.2015.01.005
44. Li Y, Sun B, Esser S, et al. Expression pattern of individual IFNA subtypes in chronic HIV infection. J Interf Cytokine Res. 2017;37:541–549. doi: 10.1089/jir.2017.0076
45. Lavoie TB, Kalie E, Crisafulli-Cabatu S, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011;56:282–289. doi: 10.1016/j.cyto.2011.07.019
46. Zscheppang K, Berg J, Hedtrich S, et al. Human pulmonary 3D models For translational research. Biotechnol J. 2018;13:1700341. doi: 10.1002/biot.201700341
47. Hocke AC, Suttorp N, Hippenstiel S., Human lung ex vivo infection models. Cell Tissue Res. 2017;367:511–524. doi: 10.1007/s00441-016-2546-z